Indian conglomerate Piramal Enterprises Limited (PEL) announced Saturday that its Pharma Solutions business has entered into a contract to purchase a solid oral dosage drug product manufacturing plant in Sellersville, PA from G&W Laboratories Inc. 

“Many of our customers are looking for US-based manufacturing partners to expand and support their pipeline. This acquisition strengthens our ability to partner with them on best-in-class drug products. It enhances our market-leading integrated services by adding a solid oral dosage capability in the US,” said Peter DeYoung, the CEO of Piramal Pharma Solutions, said in a company release. “We now offer solid oral drug product development and commercial manufacturing in all our major geographies.”

The Contract Development and Manufacturing Organization (CDMO) previously only had solid oral dosage production capabilities in the UK and India. Piramal’s newly acquired facility also supports product and process development of solid oral dosage and oral liquids, including chewable and sublingual solid oral dosage forms. The Sellersville plant has been certified by the FDA and EMA.

Located on a 31.5 acre parcel, the plant includes more than 221,000 sq ft of production space and 195,000 sq ft of GMP area. The site also contains quality control and microbiology labs, preformulation and analytical development infrastructure, a temperature-controlled warehouse, and a R&D pilot lab. 

Piramal said it plans to expand the plant’s current headcount of about 100 workers following the transaction to strengthen the site’s development services and take advantage of opportunities to produce drugs that help to manage COVID-19.